IMARX THERAPEUTICS INC (IMRX) is a publicly traded company in the Unknown sector. Across all available filings, 26 corporate insiders have executed 122 transactions totaling $23.7M, demonstrating a bullish sentiment with $15.1M in net insider flow. The most recent transaction on Feb 3, 2026 involved a transaction of 140,000 shares valued at $0.
No significant insider buying has been recorded for IMRX in the recent period.
No significant insider selling has been recorded for IMRX in the recent period.
Based on recent SEC filings, insider sentiment for IMRX is bullish with an Insider Alignment Score of 82/100 and a net flow of $15.1M. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at IMARX THERAPEUTICS INC (IMRX) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 26 insiders are actively trading IMRX stock, having executed 122 transactions in the past 90 days. The most active insider is Asset Management, Lp Cormorant (Executive), who has made 2 transactions totaling $8.3M.
Get notified when executives and directors at IMRX file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Feb 3, 2026 | Eugene Brakewood Harold | Chief Business Officer | Award | 140,000 | $N/A | $0 | |
| Feb 3, 2026 | Bookman Michael | CHIEF LEGAL OFFICER, SECRETARY | Award | 176,000 | $N/A | $0 | |
| Feb 3, 2026 | J. Zeskind Benjamin | Executive | Award | 688,000 | $N/A | $0 | |
| Feb 3, 2026 | R. Neufeld Leah | CHIEF PEOPLE OFFICER | Award | 140,000 | $N/A | $0 | |
| Feb 3, 2026 | Morales Mallory | SVP Finance, CAO | Award | 140,000 | $N/A | $0 | |
| Feb 3, 2026 | Matushansky Igor | Chief Medical Officer | Award | 140,000 | $N/A | $0 | |
| Feb 3, 2026 | Matthew Hall Brett | CHIEF SCIENTIFIC OFFICER | Award | 344,000 | $N/A | $0 | |
| Jan 16, 2026 | Eugene Brakewood Harold | Chief Business Officer | Purchase | 5,250 | $4.76 | $25.0K | |
| Jan 15, 2026 | J. Schall Thomas | Executive | Purchase | 21,645 | $4.67 | $101.0K | |
| Jan 15, 2026 | Matthew Hall Brett | CHIEF SCIENTIFIC OFFICER | Purchase | 2,298 | $4.57 | $10.5K | |
| Jan 13, 2026 | R. Neufeld Leah | CHIEF PEOPLE OFFICER | Purchase | 2,626 | $4.15 | $10.9K | |
| Jan 12, 2026 | Feinberg Peter | Executive | Purchase | 20,000 | $4.35 | $86.9K | |
| Oct 3, 2025 | Feinberg Peter | Executive | Purchase | 7,500 | $6.67 | $50.0K | |
| Oct 1, 2025 | Bookman Michael | Executive | Purchase | 1,020 | $6.83 | $7.0K | |
| Oct 1, 2025 | R. Neufeld Leah | Executive | Purchase | 800 | $6.38 | $5.1K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Purchase(P) | 63 | $19.4M | 80.8% |
Sale(S) | 16 | $4.3M | 18.0% |
Award(A) | 26 | $270.6K | 1.1% |
Exercise(M) | 3 | $19.6K | 0.1% |
Gift(G) | 2 | $0 | 0.0% |
Conversion(C) | 12 | $0 | 0.0% |
Insiders at IMARX THERAPEUTICS INC are accumulating shares at an accelerated pace. With 26 insiders making 122 transactions totaling $19.4M in purchases versus $4.3M in sales, the net buying activity of $15.1M signals strong executive confidence. Asset Management, Lp Cormorant (Executive) leads the buying activity with $8.3M in transactions across all time.